Xintela announced that the US Patent and Trademark Office (USPTO) has issued the company's patent application on chondrocyte-based cell therapy products, with validity through 2039. Xintela's US patent, US 11, 725,188, protects the development and commercialization of chondrocyte-based products that are quality assured using the cell surface markers integrin a10ß1 and integrin a11ß1. The patent is valid until 2039. Xintela has previously received patents for quality assurance of isolated and expanded chondrocytes in several countries including the US and Japan and also a product patent in Japan.

Xintela has previously reported on the company's analytical method for chondrocytes, XACT (Xintela Assay for Cell Therapy), which makes it possible to determine the quality and purity of isolated and cultured chondrocytes and develop high quality chondrocyte products for the repair of injured cartilage.